Aratana Therapeutics, Inc.
We are investigating Aratana Therapeutics, Inc. (NASDAQ GM PETX) (“Aratana Therapeutics”) regarding the sale of Aratana Therapeutics to Elanco Athens Inc. (“Elanco”). Under the terms of the proposed transaction, Aratana Therapeutics stockholders will receive .1481 shares of Elanco common stock plus one contingent value right (“CVR”) representing the right to receive $0.25 in cash if … Read more